US3960150A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bioerodible ocular device
Assignee: Alza Corp
•
Filing: 1975-09-15
•
Granted: 1976-06-01
•
Expires: 1995-09-15
Abstract
Abstract An ocular insert for the continuous controlled administration of a predetermined therapeutically effective dosage of drug to the eye over a prolonged period of time. The device meters the flow of drug by means of a drug release rate controlling material. The insert bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Inventors
- 👤 Anwar A. Hussain
- 👤 Takeru Higuchi
- 👤 John W. Shell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 03:41
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051; A61F; A61F9/00; A61F9/0008; A61F9/0017
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
148 words
A bioerodible ocular device for the controlled continuous administration of a predetermined dosage of drug to the eye, comprising a body of hydrophobic bioerodible drug release rate controlling material containing a drug confined therein, the body being of an initial shape which is adapted for insertion in the sac of the eye bounded by the surfaces of the bulbar conjunctiva of the sclera of the eyeball and the palpebral conjunctiva of the lid and being further adapted for retention in said sac during said administration, the body continuously metering the administration of a therapeutically effective amount of drug to the eye at a controlled rate for at least 8 hours by permeation control release, erosion control release or a combination thereof and wherein the body bioerodes in the environment of the eye concurrently with the administration or at a point in time after the administration of the drug.
Claim 2
Dependent Claim
148 words
A bioerodible ocular device for the controlled continuous administration of a predetermined dosage of drug to the eye, comprising a body of hydrophobic bioerodible drug release rate controlling material containing a drug confined therein, the body being of an initial shape which is adapted for insertion in the sac of the eye bounded by the surfaces of the bulbar conjunctiva of the sclera of the eyeball and the palpebral conjunctiva of the lid and being further adapted for retention in said sac during said administration, the body continuously metering the administration of a therapeutically effective amount of drug to the eye at a controlled rate for at least 8 hours by permeation control release, erosion control release or a combination thereof and wherein the body bioerodes in the environment of the eye concurrently with the administration or at a point in time after the administration of the drug.
Claim 3
Dependent Claim
23 words
The ocular device defined by claim 1 wherein the prolonged period of time is an interval of from 8 hours to 30 days.
Claim 4
Dependent Claim
33 words
The ocular device defined in claim 2 wherein the body bioerodes in the eye over a prolonged period of time in response to the environment in the eye by a process of solubilization.
Claim 5
Dependent Claim
36 words
The ocular device defined by claim 2 wherein the body bioerodes in the eye over a prolonged period of time in response to the environment in the eye by a process of hydrolysis, oxidation, or reduction.
Claim 6
Dependent Claim
34 words
The ocular device defined by claim 2 wherein the body bioerodes in the eye over a prolonged period of time in response to the environment in the eye by a process of enzymatic cleavage.
Claim 7
Dependent Claim
22 words
The ocular device defined by claim 5 wherein the device contains an added enzyme to regulate the bioerosion rate of the device.
Claim 8
Dependent Claim
36 words
The ocular device defined by claim 2 wherein the body bioerodes in the eye over a prolonged period of time in response to the environment in the eye by a process of ion exchange or displacement.
Claim 9
Dependent Claim
32 words
The ocular device defined by claim 2 wherein the continuous dispensing of a metered amount of drug from the body to the eye is effected primarily through an erosion control release mechanism.
Claim 10
Dependent Claim
29 words
The ocular device defined by claim 2 wherein the body material bioerodes in the eye at a rate of from 0.1 milligrams per day to 15 milligrams per day.
Claim 11
Dependent Claim
30 words
The ocular device defined by claim 2 wherein the device contains an added agent to regulate the bioerosion rate selected from the group consisting of binding agents and disintegrating agents.
Claim 12
Dependent Claim
33 words
The ocular device defined by claim 2 wherein the initial configuration of the body is in the shape of a donut adapted for insertion and retention surrounding the corneal area of the eye.
Claim 13
Dependent Claim
35 words
The ocular device defined by claim 2 wherein the drug is a member selected from the group consisting of epinephrine, pilocarpine, hydrocortisone, idoxuridine, tetracyclene, polymixin, gentamycin, neomycin, dexamethasone, and pharmaceutically acceptable derivatives of these drugs.
Claim 14
Dependent Claim
56 words
The ocular device defined by claim 2 wherein the drug release rate controlling material is a polyester of the general formula: ##EQU6## and mixtures thereof, wherein: W is a radical of the formula -CH 2 --; or ##EQU7## Y has a value such that the molecular weight of the polymer is from about 4,000 to 100,000.
Claim 15
Dependent Claim
22 words
The ocular device defined by claim 1 wherein the prolonged period of time is an interval of from 1 to 8 days.
References Cited (Backward Citations)
US273410A
Cited
DE1003914B
Cited
US3113076A
Cited
US3297033A
Cited
US3249109A
Cited
US3329574A
Cited
US3444858A
Cited
US3574820A
Cited
US3598122A
Cited
US3598123A
Cited
US3598122B1
Cited
US3618604A
Cited
US3630200A
Cited
US3773919A
Cited
US3640741A
Cited
US3625214A
Cited
US3641237A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-06-01 | 1979-12-01 | 1980-06-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-06-01 | 1983-12-01 | 1984-06-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-06-01 | 1987-12-01 | 1988-06-01 | $7700.00 | Window Closed / Lapsed |